Moffitt Cancer Center | Strategic Alliance Partners

July 18, 2024

A phase 1b trial is evaluating the TIL therapy TBio-4101 plus pembrolizumab in PD-(L)1 inhibitor–resistant head and neck squamous cell carcinoma.

July 15, 2024

Kedar Kirtane, MD, discusses the design of a phase 1b trial evaluating the TIL Tbio-4101 plus pembrolizumab in patients with advanced HNSCC.

July 02, 2024

Nikhil Khushalani, MD, discusses the benefits and limitations of fixed-dose treatment regimens in patients with unresectable or metastatic melanoma.

June 24, 2024

Ahmad Tarhini, MD, PhD, discusses a prognostic model evaluating patients with advanced melanoma treated with immune checkpoint inhibitors.

June 20, 2024

Roger Li, MD, discusses patient outcomes from the KEYNOTE-057 trial in BCG–unresponsive, high-risk non–muscle-invasive bladder cancer.

June 20, 2024

Kedar Kirtane, MD, discusses a phase 1b study of TBio-4101 plus pembrolizumab in patients with PD-1 inhibitor–resistant, advanced HNSCC.

June 18, 2024

Peter Forsyth, MD, discusses the importance of evaluating leptomeningeal disease caused by TNBC and HER2+ breast cancer.

May 16, 2024

Bruna Pellini, MD, highlights the multiple immunotherapies currently available for patients with NSCLC in the perioperative setting and elucidates ctDNA’s role in the treatment paradigm.

May 10, 2024

Hannah Walker-Mimms, MS, discusses a study revealing that Ewing and clear cell sarcomas have increased sensitivity to filanesib over other cancer types.

May 10, 2024

Hye Sook Chon, MD, discusses the DUO-E trial of frontline durvalumab plus chemotherapy followed by durvalumab and olaparib in endometrial cancer.

May 05, 2024

Roger Li, MD, discusses the rationale of the phase 3 MoonRISe-1 trial (NCT06319820).

May 01, 2024

Zeynep Eroglu, MD, discusses a phase 1/2 trial that evaluated ceritinib alone and in combination with trametinib in patients with mutant melanoma.

April 12, 2024

Francesco Di Meo, PhD, discusses the rationale for targeting LILRB4 through CAR T-cell therapy in multiple myeloma.

April 11, 2024

The experts provide their final thoughts surrounding the impact of prospective trials and therapy regimens for treating patients with refractory mCRC.

April 11, 2024

Key opportunities to improve the mCRC treatment landscape are illustrated by the expert panelists.

April 04, 2024

Ariel Grajales-Cruz, MD, discusses the rationale for a real-world study of teclistamab in patients with myeloma who had received BCMA-directed therapy.

April 04, 2024

Dr Kim offers key perspective for MSI-high patients based on data presented at ASCO 2024.

April 04, 2024

Multiple abstracts from ESMO 2023, including a focus on tumor location, are highlighted.

April 03, 2024

Ben Creelan, MD, discusses survival outcomes with cemiplimab in patients with squamous non–small cell lung cancer.

March 29, 2024

Rachid Baz, MD, discusses the importance of educating patients about potential adverse effects associated with multiple myeloma treatments.